A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Patients who have human leukocyte antigen (HLA)-A*24:02

• Patients who have histologically-confirmed colorectal cancer (adenocarcinoma)

• Patients with advanced or relapsed colorectal cancer who are refractory or intolerant to standard chemotherapy

• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 at the time of enrollment in the trial.

Exclusion Criteria:

• Patients who are HIV antibody test positive

• Patients with an active infection

• Patients who have or are suspected to have CNS metastasis of colon cancer (such as metastatis of the brain)